These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24029655)

  • 1. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
    Viola-Villegas NT; Rice SL; Carlin S; Wu X; Evans MJ; Sevak KK; Drobjnak M; Ragupathi G; Sawada R; Scholz WW; Livingston PO; Lewis JS
    J Nucl Med; 2013 Nov; 54(11):1876-82. PubMed ID: 24029655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
    Houghton JL; Zeglis BM; Abdel-Atti D; Sawada R; Scholz WW; Lewis JS
    J Nucl Med; 2016 Mar; 57(3):453-9. PubMed ID: 26471693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with
    Houghton JL; Abdel-Atti D; Scholz WW; Lewis JS
    Mol Pharm; 2017 Mar; 14(3):908-915. PubMed ID: 28191976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
    Escorcia FE; Steckler JM; Abdel-Atti D; Price EW; Carlin SD; Scholz WW; Lewis JS; Houghton JL
    Mol Imaging Biol; 2018 Oct; 20(5):808-815. PubMed ID: 29508263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.
    Lohrmann C; O'Reilly EM; O'Donoghue JA; Pandit-Taskar N; Carrasquillo JA; Lyashchenko SK; Ruan S; Teng R; Scholz W; Maffuid PW; Lewis JS; Weber WA
    Clin Cancer Res; 2019 Dec; 25(23):7014-7023. PubMed ID: 31540979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
    Luo G; Jin K; Deng S; Cheng H; Fan Z; Gong Y; Qian Y; Huang Q; Ni Q; Liu C; Yu X
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188409. PubMed ID: 32827580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
    Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
    Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
    J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
    Stergiou N; Nagel J; Pektor S; Heimes AS; Jäkel J; Brenner W; Schmidt M; Miederer M; Kunz H; Roesch F; Schmitt E
    Int J Med Sci; 2019; 16(9):1188-1198. PubMed ID: 31588183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
    Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
    Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
    England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
    Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.